IRIX (IRIDEX) Operating Cash Flow per Share : $-0.41 (TTM As of Mar. 2025)

View and export this data going back to 1996. Start your Free Trial

What is IRIDEX Operating Cash Flow per Share?

IRIDEX's operating cash flow per share for the three months ended in Mar. 2025 was $-0.07. IRIDEX's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.41.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for IRIDEX's Operating Cash Flow per Share or its related term are showing as below:

During the past 13 years, IRIDEX's highest 3-Year average Operating Cash Flow per Share Growth Rate was 9.20% per year. The lowest was -245.40% per year. And the median was -5.10% per year.

IRIX's 3-Year OCF Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 8.3
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

IRIDEX Operating Cash Flow per Share Historical Data

The historical data trend for IRIDEX's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Operating Cash Flow per Share Chart

IRIDEX Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.23

0.53

-0.60

-0.42

-0.44

IRIDEX Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.10	-0.08	-0.19	-0.07	-0.07

Competitive Comparison of IRIDEX's Operating Cash Flow per Share

For the Medical Devices subindustry, IRIDEX's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IRIDEX's Price-to-Operating-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IRIDEX's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where IRIDEX's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

IRIDEX Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

IRIDEX's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-7.285	/	16.439
	=	-0.44

IRIDEX's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-1.149	/	16.727
	=	-0.07

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41

IRIDEX Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of IRIDEX's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

IRIDEX Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1212 Terra Bella Avenue, Mountain View, CA, USA, 94043

Website

https://www.iridex.com

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Executives

Romeo R Dizon	other: Vice President and Controller	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
William M Moore	director
Patrick Mercer	officer: COO	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott Shuda	director	402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Beverly A Huss	director	C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Nandini Devi	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Robert Earle Grove	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp	10 percent owner	75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp	10 percent owner	111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous	director	C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne	director
Robert A Gunst	director
David Bruce	director, officer: President and CEO	1178 GLEN ROAD, LAFAYETTE CA 94549